A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma

Br J Haematol. 2019 Feb;184(3):460-462. doi: 10.1111/bjh.15107. Epub 2018 Mar 12.
No abstract available

Keywords: carfilzomib; mantle cell lymphoma; proteasome inhibition; refractory lymphoma; relapsed lymphoma.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Aged
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / mortality
  • Male
  • Middle Aged
  • Oligopeptides / administration & dosage*
  • Oligopeptides / adverse effects
  • Prospective Studies
  • Survival Rate

Substances

  • Oligopeptides
  • carfilzomib